PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT06067191
- Locations
- ๐ฌ๐ง
Pfizer, London, United Kingdom
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT06057402
- Locations
- ๐จ๐ณ
The first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
๐จ๐ฆArthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
ATGAM General Investigation
- Conditions
- Aplastic Anemia
- Interventions
- Drug: Anti-human thymocyte immunoglobulin, equine
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06039020
- Locations
- ๐ฏ๐ต
Pfizer, Tokyo, Japan
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
- Conditions
- Renal Impairment
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT06037031
- Locations
- ๐บ๐ธ
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
๐บ๐ธGenesis Clinical Research, LLC, Tampa, Florida, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT06033612
- Locations
- ๐ฌ๐ง
Richmond Pharmacology Ltd, London, Greater London, United Kingdom
A Study to Learn More About the Menopausal Hormone Therapies in Korea
- Conditions
- Bone DemineralizationMenopause
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1036294
- Registration Number
- NCT06033521
- Locations
- ๐ฐ๐ท
Pfizer South Korea, Seoul, Korea, Republic of
A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).
- Conditions
- ATTR-CM
- Interventions
- Other: Machine learning algorithm
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 558
- Registration Number
- NCT06029452
- Locations
- ๐บ๐ธ
Pfizer, New York, New York, United States
Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.
- Conditions
- Colitis, Ulcerative
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT06025227
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT06016556
- Locations
- ๐ธ๐ฆ
Saudi Arabia, Riyadh, Saudi Arabia
๐ธ๐ฆKing Faisal Specialist Hospital & research center - Jeddah, Jeddah, Saudi Arabia
๐ธ๐ฆKing Abdulaziz Medical City, Riyadh, Saudi Arabia
A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06005688
- Locations
- ๐ง๐ช
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Rรฉgion DE, Belgium